Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of VX-809 alone and when coadministered with VX-770 in subjects with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation.

Principal Investigator


Primary Contact:
Angela Leung
(650) 723-5193